Second Affiliated Hospital, School of Medicine, Zhejiang University

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

443

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

51 drugs in development

Approved1

Phase 311

Phase 217

Phase 118

Preclinical18

By Therapeutic Area

top 6

Oncology

2234%

Cardiovascular

711%

Neurology

46%

Infectious Disease

35%

Gastroenterology

35%

Ophthalmology

23%

R&D Momentum

97/100

Pipeline Velocity

82/100

Trial Completion Rate

78/100

Pipeline Concentration

19/100

Pipeline Freshness

65/100

Strategic Signals

↗Active in Musculoskeletal but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 17, 2026

Recruiting

Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial

Sep 16, 2026

Enrolling by invitation

The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction: A Prospective, Interventional, Real-World Clinical Study.

Sep 16, 2026

Recruiting

Efficacy and Safety of Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (STAR-SCLC)：A Prospective, Single Arm Trial

Earlier

Aug 13, 2026TrialAssessment of Coronary Computed Tomography-Derived Fractional Flow Reserve in Patients With Chronic Coronary Syndrome: A Prospective Multicenter Cohort Study

Aug 8, 2026TrialThe Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction: A Randomized Clinical Trial (FEND Ⅱ)

Aug 8, 2026TrialEfficacy and Safety of the Adacolumn® Granulocyte and Monocyte/Macrophage Apheresis Device for Cerebral Edema After Acute Anterior Circulation Occlusive Cerebral Infarction: A Prospective, Randomized, Controlled Clinical Trial

Aug 6, 2026TrialMulticenter Study on the Use of Intraoperative Optical Coherence Tomography in the Diagnosis and Management of Lens Diseases

Aug 4, 2026TrialA Study on the Efficacy and Safety of TEER Combined Electrical Cardioversion in Patients With Severe Mitral Regurgitation and Atrial Fibrillation: A Prospective, Multicenter, Open-Label Randomized Controlled Study

4 more events

Aug 4, 2026TrialA Multicenter Clinical Study on Transcranial Magnetic Stimulation of the Primary Motor Cortex for PTSD Treatment

Aug 4, 2026TrialA Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib (Investigational Therapy) in Patients With Moderate-to-Severe Palmoplantar Pustulosis

Jul 31, 2026TrialIntranasal Dexmedetomidine and Perioperative Myocardial Injury in Patients Having Percutaneous Coronary Interventions: A Single-Center, Prospective Randomized Controlled Pilot Study

Jul 31, 2026TrialThe Ameliorative Role of Diabetes Remission in Aging: A Real-World-Based Prospective Clinical Cohort Study

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(7 drugs)

—

Cardiovascular(7 drugs)

Dermatology(2 drugs)

—

Dermatology(2 drugs)

Gastroenterology(3 drugs)

—

Gastroenterology(3 drugs)

Hematology(2 drugs)

—

Hematology(2 drugs)

Immunology(2 drugs)

—

Immunology(2 drugs)

Infectious Disease(3 drugs)

—

Infectious Disease(3 drugs)

Metabolic & Endocrine(1 drug)

—

Metabolic & Endocrine(1 drug)

Musculoskeletal(1 drug)

—

Musculoskeletal(1 drug)

Neurology(4 drugs)

—

Neurology(4 drugs)

Oncology(22 drugs)

Ophthalmology(2 drugs)

—

Ophthalmology(2 drugs)

Psychiatry(1 drug)

—

Psychiatry(1 drug)

Unknown / Other(14 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)